Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Authors
Rudin, CHann, C
Garon, E
Ribeiro de Oliveira, M
Bonomi, P
Camidge, D
Chu, Q
Giaccone, G
Khaira, D
Ramalingam, S
Ranson, Malcolm R
Dive, Caroline
McKeegan, E
Chyla, B
Dowell, B
Chakravartty, A
Nolan, C
Rudersdorf, N
Busman, T
Mabry, M
Krivoshik, A
Humerickhouse, R
Shapiro, G
Gandhi, L
Affiliation
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 2, Room 544, 1550 Orleans Street, Baltimore, MD 21231, USA.Issue Date
2012-06-01
Metadata
Show full item recordAbstract
Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). The primary objectives of this phase IIa study included safety at the recommended phase II dose and preliminary, exploratory efficacy assessment in patients with recurrent and progressive SCLC after at least one prior therapy.Citation
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. 2012, 18 (11):3163-9 Clin Cancer ResJournal
Clinical Cancer ResearchDOI
10.1158/1078-0432.CCR-11-3090PubMed ID
22496272Type
ArticleLanguage
enISSN
1078-0432ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-11-3090